The main worries Semaglutide provides are common to all GLP-1 receptor agonists. Surprisingly, the FDA takes the pitfalls seriously ample to insist manufacturers distribute Wegovy and comparable medications with boxed warnings about cancer but it still considers the potential Added benefits outweigh the potential hazards.Serious stomach problems.